Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann. Rheum. Dis.

Title: Annals of the rheumatic diseases

Publisher: BMJ

ISSN (Electronic): 1468-2060

ISSN (Print): 0003-4967

Publication date (Electronic): June 2020

Volume: 79

Issue: 6

Affiliations

[1 ] Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands alexsepriano@gmail.com.

[2 ] NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal, Lisboa, Portugal.

[3 ] Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.

[4 ] 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria.

[5 ] Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.

[6 ] Department of Rheumatology, Hôpital Cochin. Assistance Publique - Hôpitaux de Paris, Paris, France.

[7 ] Clinical Epidemiology and Biostatistics, INSERM U1153, Paris, France.

[8 ] Department Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.

[9 ] Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

[10 ] Department of Rheumatology, University Medical Centre Utrecht, Utrecht, The Netherlands.

[11 ] Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.

[12 ] EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland.

[13 ] Center for Personalized Health, Feinstein Institute for Medical Research, Northwell Health, New York, New York, USA.

[14 ] Amsterdam University Medical Center (ARC), Amsterdam, The Netherlands.

[15 ] Department of Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands.

Article

Publisher Item ID: annrheumdis-2019-216653

DOI: 10.1136/annrheumdis-2019-216653

PubMed ID: 32033941

SO-VID: 0950e5b3-4d1c-4f79-96a1-181a9cbcd238

History

Keywords: outcomes research,DMARDs (synthetic),anti-TNF,DMARDs (biologic),rheumatoid arthritis

Data availability:

Keywords: outcomes research, DMARDs (synthetic), anti-TNF, DMARDs (biologic), rheumatoid arthritis

Comments

Comment on this article

Cited by 114

See all cited by